For citations:
Loginova E.Yu., Korotaeva T.V., Gubar E.E., Korsakova Yu.L., Sedunova M.V., Pristavskiy I.N., Kushnir I.N., Umnova I.F., Kudishina S.S., Nasonov E.L. Influence of the duration of psoriatic arthritis on the achievement of remission and minimal disease activity during therapy with genetically engineered biologic drugs. Data from the all-russian register of patients with psoriatic arthritis. Rheumatology Science and Practice. 2020;58(6):695-700. (In Russ.) https://doi.org/10.47360/1995-4484-2020-695-700
Email this article 